Bayani DB, Lin YC, Nagarajan C, Ooi MG, Tso ACY, Cairns J, Wee HL. Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers. Pharmacoecon Open. 2024 Sep;8(5):651-664. doi: 10.1007/s41669-024-00503-9. Epub 2024 Jun 20. PMID: 38900407; PMCID: PMC11362436.